This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meier, C. A. Articles by Dayer, J.-M. Search for Related Content PubMed PubMed Citation Articles by Meier, C. A. Articles by Dayer, J.-M.

IL-1 Receptor Antagonist Serum Levels Are Increased in Human Obesity: A Possible Link to the Resistance to Leptin?

Divisions of Endocrinology and Diabetes (C.A.M.), Therapeutic Teaching (E.B., A.G.), Rheumatology (C.G.), and Immunology and Allergy (J.-M.D.), Department of Internal Medicine, University Hospital Geneva; and Department of Medical Biochemistry, Centre Médical Universitaire (F.A.-J.), CH-1211 Geneva, Switzerland

Address all correspondence and requests for reprints to: Dr. Christoph A. Meier, Endocrine Unit, Division of Endocrinology and Diabetes, University Hospital Geneva, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland. E-mail: . cameier{at}bluewin.ch

Abstract

We have recently shown that human monocytic cells express functional leptin receptors and that leptin is capable of inducing the expression and secretion of the IL-1 receptor antagonist (IL-1Ra). Although IL-1Ra has anti-inflammatory and possibly anti-atherogenic properties, it has also been shown to antagonize the action of leptin at the hypothalamic level in rodents, thereby inducing leptin resistance. We have therefore examined whether IL-1Ra levels are increased in human hyperleptinemic conditions, such as obesity.

To this end, we measured serum IL-1Ra levels in 20 morbidly obese nondiabetic subjects [body mass index (BMI), 45 ± 6 kg/m²; serum leptin, 52 ± 20 ng/ml] as well as in 10 age- and sex-matched lean controls (BMI, 22 ± 2 kg/m²; serum leptin, 7 ± 4 ng/ml). Serum IL-1Ra concentrations proved to be elevated 6.5-fold in the obese subjects, and they were positively correlated in a linear manner with the leptin levels (r² = 0.34; P = 0.01), although lean body mass (LBM) and the insulin resistance index were even better predictors of IL-1Ra levels (r² = 0.45 and 0.58, respectively; P < 0.01). Six months after 15 of the 20 obese subjects had undergone bypass surgery for their morbid obesity, their mean BMI and leptin levels decreased to 33 ± 7 kg/m² and 18 ± 12 ng/ml, respectively. This change in leptin concentrations was associated with a significant reduction in IL-1Ra levels (P < 0.02). However, there was a better correlation between the decrease in IL-1Ra level and the change in LBM than with the reduction in leptin levels, indicating that leptin is not the sole determinant of circulating IL-1Ra in obesity.

In summary, we demonstrate that IL-1Ra levels are highly elevated in human obesity and that its concentrations decrease after weight loss from bypass surgery. However, LBM and insulin resistance are better predictors of serum IL-1Ra concentrations than are leptin levels, suggesting that additional metabolic factors control the secretion of this cytokine antagonist. Although the immunological consequences of this alteration remain unknown, it is tempting to speculate that the obesity-related increase in IL-1Ra might contribute to the central resistance to leptin in obese patients, similar to the inhibition of the hypothalamic signaling of leptin by IL-1Ra in rodents.

This article has been cited by other articles:

				D. Hofso, T. Ueland, H. Hager, T. Jenssen, J. Bollerslev, K. Godang, P. Aukrust, J. Roislien, and J. Hjelmesaeth Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose Eur. J. Endocrinol., September 1, 2009; 161(3): 451 - 458. [Abstract] [Full Text] [PDF]

				C. L. Sherry, S. S. Kim, and G. G. Freund Accelerated Recovery from Acute Hypoxia in Obese Mice Is Due to Obesity-Associated Up-Regulation of Interleukin-1 Receptor Antagonist Endocrinology, June 1, 2009; 150(6): 2660 - 2667. [Abstract] [Full Text] [PDF]

				C. Herder, E. J. Brunner, W. Rathmann, K. Strassburger, A. G. Tabak, N. C. Schloot, and D. R. Witte Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study Diabetes Care, March 1, 2009; 32(3): 421 - 423. [Abstract] [Full Text] [PDF]

				H. Forsblad d'Elia, R. Pullerits, H. Carlsten, and M. Bokarewa Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis Rheumatology, July 1, 2008; 47(7): 1082 - 1087. [Abstract] [Full Text] [PDF]

				C. Pfleger, H. B. Mortensen, L. Hansen, C. Herder, B. O. Roep, H. Hoey, H.-J. Aanstoot, M. Kocova, N. C. Schloot, and on behalf of the Hvidore Study Group on Childhood Association of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 Diabetes Diabetes, April 1, 2008; 57(4): 929 - 937. [Abstract] [Full Text] [PDF]

				J. Saltevo, M. Vanhala, H. Kautiainen, and M. Laakso Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 328 - 331. [Abstract] [PDF]

				S. Thalmann and C. A. Meier Local adipose tissue depots as cardiovascular risk factors Cardiovasc Res, September 1, 2007; 75(4): 690 - 701. [Abstract] [Full Text] [PDF]

				T. Skurk, C. Alberti-Huber, C. Herder, and H. Hauner Relationship between Adipocyte Size and Adipokine Expression and Secretion J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1023 - 1033. [Abstract] [Full Text] [PDF]

				E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen, J. Pihlajamaki, K. Punnonen, S. Kainulainen, and M. Laakso Changes in Inflammatory Cytokines Are Related to Impaired Glucose Tolerance in Offspring of Type 2 Diabetic Subjects Diabetes Care, December 1, 2006; 29(12): 2714 - 2720. [Abstract] [Full Text] [PDF]

				L. Strandberg, M. Lorentzon, A. Hellqvist, S. Nilsson, V. Wallenius, C. Ohlsson, and J.-O. Jansson Interleukin-1 System Gene Polymorphisms Are Associated with Fat Mass in Young Men J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2749 - 2754. [Abstract] [Full Text] [PDF]

				M. C. Garcia, I. Wernstedt, A. Berndtsson, M. Enge, M. Bell, O. Hultgren, M. Horn, B. Ahren, S. Enerback, C. Ohlsson, et al. Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes, May 1, 2006; 55(5): 1205 - 1213. [Abstract] [Full Text] [PDF]

				D. Chida, T. Osaka, O. Hashimoto, and Y. Iwakura Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes, April 1, 2006; 55(4): 971 - 977. [Abstract] [Full Text] [PDF]

				E. Somm, E. Henrichot, A. Pernin, C. E. Juge-Aubry, P. Muzzin, J.-M. Dayer, M. J.H. Nicklin, and C. A. Meier Decreased Fat Mass in Interleukin-1 Receptor Antagonist-Deficient Mice: Impact on Adipogenesis, Food Intake, and Energy Expenditure Diabetes, December 1, 2005; 54(12): 3503 - 3509. [Abstract] [Full Text] [PDF]

				J. J. Puder, S. Varga, M. Kraenzlin, C. De Geyter, U. Keller, and B. Muller Central Fat Excess in Polycystic Ovary Syndrome: Relation to Low-Grade Inflammation and Insulin Resistance J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6014 - 6021. [Abstract] [Full Text] [PDF]

				B. J. Nicklas, T. You, and M. Pahor Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training Can. Med. Assoc. J., April 26, 2005; 172(9): 1199 - 1209. [Abstract] [Full Text] [PDF]

				C. E. Juge-Aubry, E. Somm, R. Chicheportiche, D. Burger, A. Pernin, B. Cuenod-Pittet, P. Quinodoz, V. Giusti, J.-M. Dayer, and C. A. Meier Regulatory Effects of Interleukin (IL)-1, Interferon-{beta}, and IL-4 on the Production of IL-1 Receptor Antagonist by Human Adipose Tissue J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2652 - 2658. [Abstract] [Full Text] [PDF]

				K. Maedler, P. Sergeev, J. A. Ehses, Z. Mathe, D. Bosco, T. Berney, J.-M. Dayer, M. Reinecke, P. A. Halban, and M. Y. Donath Leptin modulates {beta} cell expression of IL-1 receptor antagonist and release of IL-1{beta} in human islets PNAS, May 25, 2004; 101(21): 8138 - 8143. [Abstract] [Full Text] [PDF]

				C. E. Juge-Aubry, E. Somm, V. Giusti, A. Pernin, R. Chicheportiche, C. Verdumo, F. Rohner-Jeanrenaud, D. Burger, J.-M. Dayer, and C. A. Meier Adipose Tissue Is a Major Source of Interleukin-1 Receptor Antagonist: Upregulation in Obesity and Inflammation Diabetes, May 1, 2003; 52(5): 1104 - 1110. [Abstract] [Full Text] [PDF]

				T. Ueland, C. Kristo, K. Godang, P. Aukrust, and J. Bollerslev Interleukin-1 Receptor Antagonist Is Associated with Fat Distribution in Endogenous Cushing's Syndrome: A Longitudinal Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1492 - 1496. [Abstract] [Full Text] [PDF]